This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
After hours of company pushback, FDA’s Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or no PD-L1 expressors doesn’t outweigh the risks.
Medscape Medical News